Stockscreener 앱 받기
6.36
5.22%
-0.35
시간 외 거래:
6.40
0.04
+0.63%
전일 마감가:
$6.71
열려 있는:
$6.52
하루 거래량:
1.75M
Relative Volume:
0.97
시가총액:
$666.03M
수익:
$69.65M
순이익/손실:
$-81.27M
주가수익비율:
-6.9982
EPS:
-0.9088
순현금흐름:
$-79.45M
1주 성능:
+6.35%
1개월 성능:
-4.07%
6개월 성능:
-15.31%
1년 성능:
+30.06%
1일 변동 폭
$6.32
$6.59
1주일 범위
$5.70
$7.3925
52주 변동 폭
$3.84
$11.50
Personalis Inc Stock (PSNL) Company Profile
명칭
Personalis Inc
전화
650-752-1300
주소
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
6.36 | 702.68M | 69.65M | -81.27M | -79.45M | -0.9088 |
TMO
Thermo Fisher Scientific Inc
|
438.34 | 166.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
161.91 | 116.46B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.79 | 42.03B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
329.22 | 32.72B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
111.70 | 32.01B | 7.07B | 1.29B | 993.00M | 4.5355 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-05-15 | 개시 | Guggenheim | Buy |
| 2025-03-17 | 개시 | Craig Hallum | Buy |
| 2023-02-06 | 업그레이드 | Needham | Hold → Buy |
| 2022-01-07 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | 다운그레이드 | Needham | Buy → Hold |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-20 | 재확인 | Needham | Buy |
| 2021-05-06 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-01-28 | 개시 | Truist | Buy |
| 2021-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-11-12 | 재확인 | Needham | Buy |
| 2020-11-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-08-27 | 개시 | H.C. Wainwright | Buy |
| 2020-08-18 | 개시 | Needham | Buy |
| 2019-09-26 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | 개시 | BofA/Merrill | Neutral |
| 2019-07-15 | 개시 | Cowen | Outperform |
| 2019-07-15 | 개시 | Morgan Stanley | Overweight |
| 2019-07-15 | 개시 | Oppenheimer | Outperform |
모두보기
Personalis Inc 주식(PSNL)의 최신 뉴스
Personalis rises as Medicare coverage for NeXT Personal test expands - MSN
Personalis to Participate in Upcoming Investor Events - BioSpace
[Form 4] Personalis, Inc. Insider Trading Activity - Stock Titan
Personalis (NASDAQ: PSNL) director granted 6,250 RSUs and 37,500 options - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and 37,500-share stock option - Stock Titan
Personalis (NASDAQ: PSNL) director granted RSUs and options as board pay - Stock Titan
Personalis (PSNL) director Olivia Bloom granted RSUs and 37,500 options - Stock Titan
Personalis (PSNL) director receives 6,250 RSUs and 37,500 options - Stock Titan
Personalis Shares Rise on Medicare Coverage for Immunotherapy Monitoring - Moomoo
Personalis Shareholders Back Directors, Auditor and Executive Pay - TipRanks
Personalis shareholders elect directors and approve proposals at annual meeting - Investing.com India
Lake Street Initiates Personalis(PSNL.US) With Buy Rating, Announces Target Price $11 - Moomoo
Personalis (NASDAQ: PSNL) investors back directors, executive pay and BDO as auditor - Stock Titan
Expanded Medicare coverage for Personalis (NASDAQ: PSNL) NeXT Personal test - Stock Titan
Personalis Inc (NASDAQ: PSNL) Share Price, PSNL Stock News, PSNL Share Price & Updates - Kalkine
Personalis (PSNL) Q1 2026 Earnings Transcript - AOL.com
Personalis (PSNL) Expands Coverage for NeXT Personal MRD Test - GuruFocus
Why is Personalis stock surging today? By Investing.com - Investing.com Canada
Personalis receives Medicare coverage for Next Personal for immunotherapy monitoring across late-stage solid tumors - marketscreener.com
Personalis gains expanded Medicare coverage for cancer test - Investing.com
Personalis gains expanded Medicare coverage for cancer test By Investing.com - Investing.com UK
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors - Business Wire
PSNL Maintained by Morgan Stanley -- Price Target Lowered to $9. - GuruFocus
Deep Track (PSNL) discloses 5.51% holding in Personalis as of May 12, 2026 - Stock Titan
PSNL: Directors and auditors elected, executive pay approved, with strong growth and AI focus - TradingView
Morgan Stanley Cuts Price Target on Personalis to $9 From $10, Keeps Equalweight Rating - Moomoo
Personalis outlines 2026 clinical volume target of 43,000 to 45,000 tests while reaffirming $78M to $80M revenue guidance - MSN
Morgan Stanley Maintains Personalis(PSNL.US) With Hold Rating, Cuts Target Price to $5.78 - Moomoo
PSNL Maintained by BTIG -- Price Target Lowered to $11.00 - GuruFocus
BTIG Research Issues Pessimistic Forecast for Personalis (NASDAQ:PSNL) Stock Price - MarketBeat
BTIG Maintains Personalis(PSNL.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
BTIG cuts Personalis stock price target on lab sector valuation - Investing.com
BTIG cuts Personalis stock price target on lab sector valuation By Investing.com - Investing.com Nigeria
Personalis, Inc. (NASDAQ:PSNL) Q1 2026 Earnings Call Transcript - Insider Monkey
Guggenheim Remains a Buy on Personalis (PSNL) - The Globe and Mail
Personalis (NASDAQ:PSNL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Personalis Q1 Earnings Call Highlights - Barchart.com
TD Cowen Maintains Personalis(PSNL.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Q1 2026 Personalis Inc Earnings Call Transcript - GuruFocus
Guggenheim Maintains Personalis(PSNL.US) With Buy Rating, Maintains Target Price $13 - Moomoo
Needham reiterates Personalis stock rating citing MRD growth By Investing.com - Investing.com Australia
Personalis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Needham reiterates Personalis stock rating citing MRD growth - Investing.com UK
Personalis, Inc. (PSNL) Stock Analysis: Navigating a Promising 88% Upside in Healthcare Genomics - DirectorsTalk Interviews
Personalis: Q1 Earnings Snapshot - theheraldreview.com
Personalis Reports First Quarter Results and Recent Highlights - BioSpace
Earnings call transcript: Personalis Q1 2026 sees revenue beat, EPS miss - Investing.com
Earnings call transcript: Personalis Q1 2026 sees revenue beat, EPS miss By Investing.com - Investing.com South Africa
Personalis Inc (PSNL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.71%
자본화:
|
볼륨(24시간):